You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
NameLutropin alfa
Accession NumberDB00044  (BTD00056, BIOD00056)
DescriptionLutropin alfa is a recombinant human luteinizing hormone produced in yeast with 2 subunits, alpha = 92 residues, beta = 121 residues. It is a heterodimeric glycoprotein. Each monomeric unit is a glycoprotein molecule. In females, an acute rise of LH ("LH surge") triggers ovulation and the development of the corpus luteum. In males, it stimulates Leydig cell production of testosterone. Lutropin alfa was the first and only recombinant human form of luteinizing hormone (LH) developed for use in the stimulation of follicular development.
Protein structureDb00044
Related Articles
Protein chemical formulaC1014H1609N287O294S27
Protein average weight30000.0 Da
>Alpha Chain
>Beta Chain (LH)
Download FASTA Format
Insterstiial cell-stimulating hormone
LSH- beta
Luteinizing hormone
Luteinizing hormone beta subunit
Lutropin alpha
Lutropin beta chain precursor
External IDs Not Available
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LuverisPowder, for solution75 unitSubcutaneousEmd Serono, A Division Of Emd Inc., Canada2005-06-28Not applicableCanada
LuverisSolution450 unitSubcutaneousEmd Serono, A Division Of Emd Inc., CanadaNot applicableNot applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
Humegon Inj 75 I.U.Organon Canada Ltd Ltee
Pergonal 75 I.U.Emd Serono, A Division Of Emd Inc., Canada
PergoverisEmd Serono, A Division Of Emd Inc., Canada
CAS number152923-57-4
IndicationFor treatment of infertility in women with hypothalamic or pituitary insufficiency (hypogonadotropic hypogonadism) and profound LH deficiency (LH <1.2 international units [IU]/L)
Structured Indications
PharmacodynamicsUsed to facilitate female conception, lutropin alfa performs the same actions as luteinizing hormone (LH), which is normally produced in the pituitary gland. Lutropin is usually given in combination with follitropin alfa. Together they stimulate the development of a follicle to prepare the reproductive tract for implementation and pregnancy. Lutropin alfa also stimulates the theca cells to produce androgens and the secretion of estradiol by the follicles. Lutropin alfa and follitropin alfa are discontinued once ultrasound assessment and serum estradiol concentrations show sufficient follicular maturation. hCG is then administered to complete follicular maturation and induce ovulation. In females, a LH surge about halfway through the menstrual cycle triggers the onset of ovulation. Lutropin alfa substitutes for endogenous LH and induces rupture of the preovulatory ovarian follicle and oocyte expulsion. Lutropin alfa induces and maintains the corpus luteum, which then secretes progesterone.
Mechanism of actionLuteinizing hormone binds to a receptor shared with the human chorionic gonadotropin hormone (hCG) on the ovarian theca (and granulosa) cells and testicular Leydig cells. This LH/CG transmembrane receptor is a member of the super-family of G protein-coupled receptors. Adenylate cyclase then activates many other pathways leading to steroid hormone production and other follicle maturation processes.
TargetKindPharmacological actionActionsOrganismUniProt ID
Lutropin-choriogonadotropic hormone receptorProteinyes
HumanP22888 details
Related Articles
AbsorptionMean absolute bioavailability is 56%, following sub-Q administration, maximum serum concentrations reached after 4–16 hours. Time to peak, serum: 9 hours
Volume of distribution

The steady state volume of distribution is around 10-14 L.

Protein bindingNot Available

<5% of dose excreted renally as unchanged drug.

Route of eliminationTotal body clearance is approximately 2 to 3 L/h with less than 5 percent of the dose being excreted unchanged renally.
Half lifeBiphasic; terminal half-life is approximately 18 hours.
  • 2 – 3 L/h [healthy female following subcutaneous administration]
ToxicityLutropin alfa is not indicated for people under 16 and over 60, pregnant and lactating women, patients with uncontrolled thyroid and adrenal failure, patients with active, untreated tumours of the hypothalamus and pituitary gland, and in any patient with a condition that makes a normal pregnancy possible such as primary ovarian failure or fibroid tumors of the uterus.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Drug Interactions No interactions found.
Food InteractionsNot Available
Synthesis ReferenceNot Available
General References
  1. Blanchard J: Gastrointestinal absorption. I. Mechanisms. Am J Pharm Sci Support Public Health. 1975 Sep-Oct;147(5):135-46. [PubMed:3972 ]
  2. Louvet JP, Harman SM, Ross GT: Effects of human chorionic gonadotropin, human interstitial cell stimulating hormone and human follicle-stimulating hormone on ovarian weights in estrogen-primed hypophysectomized immature female rats. Endocrinology. 1975 May;96(5):1179-86. [PubMed:1122882 ]
  3. Nielsen MS, Barton SD, Hatasaka HH, Stanford JB: Comparison of several one-step home urinary luteinizing hormone detection test kits to OvuQuick. Fertil Steril. 2001 Aug;76(2):384-7. [PubMed:11476792 ]
  4. Gibreel A, Bhattacharya S: Recombinant follitropin alfa/lutropin alfa in fertility treatment. Biologics. 2010 Feb 4;4:5-17. [PubMed:20161981 ]
  5. Dhillon S, Keating GM: Lutropin alfa. Drugs. 2008;68(11):1529-40. [PubMed:18627209 ]
  6. Link [Link]
External Links
ATC CodesG03GA07
AHFS Codes
  • 68:18.00
PDB Entries
FDA labelDownload (218 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
2CompletedTreatmentControlled Ovarian Stimulation1
2CompletedTreatmentInfertilities / Ovulation induction therapy1
2TerminatedTreatmentInfertilities / Ovulation induction therapy2
2Unknown StatusTreatmentInfertilities1
3CompletedTreatmentAssisted Reproductive Techniques / Reproductive Technology, Assisted1
3CompletedTreatmentInfertilities / Ovarian Stimulation1
3TerminatedSupportive CareFertility / Follicle Stimulating Hormone Deficiency / Infertilities1
4CompletedTreatmentAssisted Reproductive Technology therapy / Infertilities1
4CompletedTreatmentInfertility, Female Infertility, Male Infertility1
4Not Yet RecruitingTreatmentInfertility, Female1
4TerminatedTreatmentHypogonadotropic Hypogonadism1
4Unknown StatusTreatmentInfertilities1
Not AvailableCompletedNot AvailableBMI >30 kg/m21
Not AvailableCompletedScreeningOther Diseases or Conditions1
Not AvailableCompletedTreatmentHypogonadotropic Hypogonadism1
Not AvailableCompletedTreatmentInfertilities1
Not AvailableCompletedTreatmentOutcome During r-hFSH and r-hLH Stimulation / Outcome During r-hFSH Stimulation1
Not AvailableUnknown StatusTreatmentComplications Associated With Artificial Fertilization / Female Infertility Due to Nonimplantation of Ovum1
  • Emd serono inc
Dosage forms
Liquid; powder, for solutionIntramuscular
Powder, for solutionSubcutaneous75 unit
SolutionSubcutaneous450 unit
Powder, for solutionIntramuscular
Kit; powder, for solutionSubcutaneous
Unit descriptionCostUnit
Luveris 75 unit vial38.88USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5767251 No1995-06-162015-06-16Us
Experimental Properties
melting point55 °CForastieri, H., Ingham, K.C. J. Biol. Chem. 257:7976-7981 (1982)
hydrophobicity-0.063Not Available
isoelectric point8.44Not Available
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available


Pharmacological action
General Function:
Luteinizing hormone receptor activity
Specific Function:
Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase.
Gene Name:
Uniprot ID:
Molecular Weight:
78642.01 Da
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Gibreel A, Bhattacharya S: Recombinant follitropin alfa/lutropin alfa in fertility treatment. Biologics. 2010 Feb 4;4:5-17. [PubMed:20161981 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23